Revitalist Reports Clinic Visit Increase of 273% in January 2022

Share Post:

VANCOUVER, BC, February 8, 2022 – REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company”) (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO) is pleased to announce patient visits for the month of January 2022 increased by 273% year over year.  The Company has significantly scaled its operations in the last twelve months and expects to continue the upward trajectory of patient visits as it calibrates it’s operational and marketing infrastructure.  Monthly visits are summarized in the chart below.

CEO, Kathryn Walker states, “January 2022 was a milestone for patient visits at Revitalist. With eight clinics accepting patients we saw our highest historical monthly patient count.  Revitalist is practicing translational medicine and aims to improve global healthcare in a significant way.  Our patient visits are a transparent measure of our progress towards this goal and an indicator which allows us to evaluate contributions to our communities and performance relative to our competition. I’d like to thank the entire team at Revitalist who are working tirelessly to ensure that we offer world-class service to our patients and solidify our brand in the marketplace.” 

ABOUT REVITALIST LIFESTYLE AND WELLNESS LTD.

Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO) is a publicly traded company, headquartered in Knoxville, Tennessee, with clinics operating across the United States and expanding. Revitalist is dedicated to empowering individuals toward an improved quality of well-being through a combination of comprehensive care and future-centric treatments provided by medical professionals, mental health experts, and chronic pain specialists. The company proudly practices translational medicine  which is supported by three main pillars: benchside, bedside and community, with a goal to improve the global healthcare system significantly.  Since opening their first clinic in 2018, Revitalist has provided thousands of infusions for patients suffering from treatment-resistant conditions. Additionally, Revitalist offers a number of lifestyle optimization services and vitamin infusions that can bring anyone closer to total wellness. For additional information and to be added to the Company’s mailing list, please click here.

Twitter:                @RevitalistCorp

Facebook:           @RevitalistLifestyleandWellnessLtd.

Instagram:          @RevitalistCorp

LinkedIn:             @RevitalistLifestyleAndWellnessLtd

 

On Behalf of the Board

Kathryn Walker

Chief Executive Officer

 

For further information please contact:

Revitalist Lifestyle and Wellness Ltd.

Email: [email protected]

Tel: (865) 585-8414

 

Forward Looking Statements

This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Revitalist to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release.  

Risks, uncertainties, and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Stay Connected

More Press Releases

Psychedelic Community Reacts To FDA Committee’s Critique Of Lykos’ MDMA Studies Guest Column | June 14, 2024 As told to Abby Proch, executive editor of